Osteofos

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Osteofos

Quick Facts

Property Description
Active Ingredients Calcium Carbonate, Dihydrotachysterol
Form Oral preparation (Tablet or Capsule)
Pharmacological Class Calcium Regulator, Vitamin D Analog Combination
General Purpose Supporting calcium homeostasis and bone mineralization
Origin Inorganic salt (Calcium Carbonate) and Synthetic analog (Dihydrotachysterol)

What Type of Medicine is Osteofos? (Identity and Classification)

Osteofos is a prescription medicine formally classified as a calcium regulator and a fixed-dose combination (FDC) product intended for oral administration. Dihydrotachysterol is categorized under Vitamin D and analogues (A11CC02), reflecting its role in mineral metabolism. The medicine belongs to the therapeutic class of agents used to manage the fundamental calcium balance systemically. This specific formulation is clinically recognized for targeting patient populations with distinct needs for enhanced mineral regulation, as its combination of components addresses two crucial aspects of metabolic health.

Active Ingredients and Unique Composition

The medicine’s composition includes two key active ingredients: the inorganic salt Calcium Carbonate and the synthetic Vitamin D analog Dihydrotachysterol. Calcium Carbonate serves as a high-potency source of elemental calcium, the structural mineral required by the skeleton. Dihydrotachysterol is a synthetic secosteroid that, unlike Cholecalciferol (Vitamin D3), is designed to efficiently enhance the body's intestinal absorption of calcium. Such Vitamin D compounds are essential for regulating calcium and phosphorus levels in the body.

General Purpose: Supporting Calcium Homeostasis

The core purpose of Osteofos is to support calcium homeostasis, which is the precise maintenance of essential calcium levels in the bloodstream. By providing both the mineral (Ca^2+ ions) and the regulatory analog, the drug aids in bone mineralization, ensuring that calcium is effectively utilized by the skeleton for strength and density. A typical scenario involves using the medication to ensure adequate mineral support for the skeletal system when the body’s natural ability to regulate calcium is compromised.

What side effects are possible with Osteofos?

Possible Side Effects and Safety Information

The safety profile of Osteofos (Calcium Carbonate and Dihydrotachysterol) is primarily defined by the risk of mineral imbalance, specifically the development of elevated calcium levels in the blood (hypercalcaemia) and urine (hypercalciuria). These effects are classified in regulatory documents as Uncommon (occurring in 0.1% to 1% of patients).


Documented Adverse Reactions

Adverse reactions are formally categorized by the affected System-Organ Class (SOC). Effects related to the Metabolism and Nutrition Disorders include hypercalcaemia and hypercalciuria. Reactions within the Gastrointestinal Disorders SOC, such as nausea, constipation, and abdominal pain, are typically reported as Rare (0.01% to 0.1%).

System-Organ Class Example Adverse Reaction (Regulatory Status)
Metabolism & Nutrition Hypercalcaemia (Uncommon)
Gastrointestinal Disorders Constipation, Abdominal pain (Rare)
Renal and Urinary Disorders Hypercalciuria, Nephrocalcinosis

Serious Safety Considerations and Restrictions

Chronic or severe hypercalcaemia is associated with the risk of serious adverse reactions, including irreversible damage to the kidneys (renal damage) and generalized soft tissue calcification. The label specifies that toxic effects from the Vitamin D component may persist for up to one month after discontinuation.

Safety restrictions prohibit the use of Osteofos in individuals with pre-existing conditions such as hypercalcaemia, hypercalciuria, or severe renal impairment (GFR less than 30 ml/min/1.73 m^2). Caution is also mandated due to the potential for hypercalcaemia to enhance the toxic effects of cardiac glycosides, and use during lactation is generally contraindicated.

Overdose and Emergency Response

Overdose Symptoms and Emergency Action for Osteofos

Oral overdosage of Osteofos (alendronate) may lead to two main types of clinical manifestations: disturbances in mineral balance and upper gastrointestinal injury.

Potential Physiological Manifestations:

  • Mineral Imbalance: Overdosage can result in hypocalcemia (low calcium levels) and hypophosphatemia (low phosphate levels). Symptoms of low calcium may include muscle spasms or tingling, requiring prompt attention.
  • Gastrointestinal Distress: Signs of overdose affecting the digestive tract are often severe upper gastrointestinal adverse reactions, such as an upset stomach, heartburn, esophagitis (inflammation of the esophagus), gastritis, or a gastric ulcer.

Urgent Management and Response:

If an overdose is suspected, immediate medical attention is required to manage potential complications. Official management guidelines for an oral overdose recommend specific procedural instructions:

  • Do not induce vomiting due to the serious risk of further damage to the esophagus.
  • The patient should remain fully upright (sitting or standing).
  • Milk or antacids should be administered to help bind the alendronate and minimize its absorption into the body.

Any unusual symptoms or suspected overdose should be reported immediately to emergency services or a poison control center.

Therapeutic Uses of Osteofos

What Osteofos Treats: Main Uses and Benefits

Osteofos is primarily used to address clinical conditions resulting from the body's inability to maintain a proper mineral balance, focusing on managing symptoms related to systemic imbalance and supporting skeletal health. The key component, Dihydrotachysterol, is relevant in contexts marked by increased discomfort or tension and conditions such as hypocalcemia, hypoparathyroidism, rickets, and osteomalacia.

The medicine is used to treat conditions marked by low calcium levels in the blood. Its use contributes to improved comfort during periods of symptoms related to heightened physiological activity. It is applied in addressing symptoms of increased neurological or muscular activity, such as muscle cramps, spasms, or tingling sensations.

“The medication may assist with maintaining functional stability.”

Osteofos is also applied across domains where additional symptomatic support is needed for conditions like Osteomalacia and Renal Osteodystrophy (bone disease associated with kidney failure). It functions by supporting essential mineral balance, which helps improve day-to-day comfort during symptomatic periods and helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Support for Symptoms of Systemic Imbalance

Therapeutic Focus Primary Benefit (Supportive) Patient Group Context
Symptom Easing May assist with easing muscle cramps and spasms. Patients with Hypocalcemia.
Skeletal Support Is relevant for easing the risk of pathological fractures. Patients with Metabolic Bone Diseases.
Chronic Care Contributes to improved comfort during symptomatic phases. Patients with CKD or Hypoparathyroidism.

Eligibility and Restrictions for Use

Who Can and Cannot Use Osteofos?

Eligibility for Osteofos (Dihydrotachysterol and Calcium Carbonate) is strictly defined by regulatory documents, focusing primarily on a patient's pre-existing metabolic and physiological status. Use is established for Adults and the Elderly for treating specific mineral imbalances.


Contraindicated Populations

The medicine must not be used in patients with Hypercalcaemia (high blood calcium levels), Hypervitaminosis D, or known Hypersensitivity to the active ingredients. It is also contraindicated in individuals with Nephrolithiasis (kidney stones), Nephrocalcinosis, or conditions that cause hypercalcaemia, such as primary hyperparathyroidism or bone metastases. Use is contraindicated during Lactation (breastfeeding).


Restricted and Age-Related Use

Use is not recommended in patients with severe renal impairment (Glomerular Filtration Rate typically below 30 mL/min) and requires caution with monitoring in all other degrees of renal impairment. For Pregnancy, the medicine is restricted and only justified if the potential benefit outweighs the possible risk. The combination product's use is generally not established in the pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the active ingredients in Osteofos (mathbfCalcium Carbonate and mathbfDihydrotachysterol), based strictly on regulatory prescribing information.


Pharmacodynamic and Cardiac Interactions

Interacting Product Category Official Interaction Description
Digitalis Compounds (e.g., Digoxin) mathbfIncreased risk of ventricular arrhythmias and cardiac toxicity, which may be exacerbated by hypercalcemia.
Thiazide Diuretics (e.g., Chlorothiazide) mathbfAdditive pharmacodynamic effect increasing the risk of hypercalcemia (high calcium levels).
Other Vitamin D Analogs Concurrent use may lead to mathbfadditive effects or toxicity (hypercalcemia) and is generally to be avoided.

Pharmacokinetic and Absorption Interference

Interacting Product Category Official Interaction Description
Bile Acid Sequestrants (e.g., Cholestyramine) May mathbfdecrease the serum concentration of Dihydrotachysterol, reducing exposure.
Anticonvulsants (e.g., Phenobarbital) Can mathbfreduce the half-life of Vitamin D compounds through increased hepatic metabolism.

Administration Requirements and Dietary Notes

To prevent absorption interference, regulatory documents indicate that mathbfCalcium supplements must be taken at least 30 minutes after certain mathbfbisphosphonates. Furthermore, mathbffoods high in oxalic or phytic acid may mathbfdecrease calcium absorption, and taking mathbfCalcium Carbonate with food may mathbfincrease its absorption. Specific mathbfcaution is noted for patients with mathbfimpaired renal function who are more susceptible to toxic effects.

Mechanism of Action

Targeted Bone Mineral Binding and Selective Uptake

Osteofos (alendronate) exhibits a high affinity for the hydroxyapatite mineral in bone, localizing the drug specifically to active bone resorption sites. This selective targeting contributes to the molecule being preferentially taken up by the bone-dissolving cells, the osteoclasts, during their normal function.

Disruption of Intracellular Signaling Cascade

Once internalized, the drug functions as an inhibitor of the enzyme Farnesyl Diphosphate Synthase (FDPS) within the osteoclast. This molecular action disrupts the Mevalonate Pathway and prevents the proper functioning of critical regulatory proteins, leading directly to the apoptosis (programmed death) of the osteoclast.

Suppression of Bone Resorption

The elimination of active osteoclasts causes a sustained suppression of the bone resorption rate (bone turnover). This shift in skeletal homeostasis allows the bone-building processes to proceed relatively unopposed, resulting in a net physiological shift in the bone remodeling balance toward accumulation of bone mineral.

Dosage and Administration Information

How to Use Osteofos: Official Administration Guidelines

Osteofos is a fixed-dose combination product formulated exclusively for oral administration as a tablet or capsule. The usage protocol is structured around the high-level requirements for its active components, which necessitate a carefully monitored, long-term regimen. The medicine is consistently taken once daily (q.d.) for chronic management.

Dosing and Schedule

Administration follows a two-phase sequence: an initial loading period and a long-term maintenance phase. For the Dihydrotachysterol component, the initial regimen for conditions such as hypoparathyroidism typically involves 0.8 mg to 2.4 mg once daily for several days to achieve systemic stability. This is followed by a maintenance dose that typically ranges from 0.2 mg to 1.0 mg once daily. Dose adjustments must be conducted slowly, occurring over intervals of four to eight weeks following clinical assessment.

Administration Context and Monitoring

A fundamental procedural requirement for this combination is the mandatory provision of oral calcium throughout the entire course of therapy, a need which the combination's Calcium Carbonate component is designed to meet. The administration protocol is strictly governed by the need for frequent serum monitoring. During the initial dose titration phase, serum calcium levels must be checked one to two times per week, and at least monthly once the maintenance dose is stabilized, as required by official administration guidelines. Furthermore, specific dosage tables are officially established for use in pediatric populations when indicated.

Recent Clinical Evidence

Evidence for use in Chronic Hypoparathyroidism

Research has explored Dihydrotachysterol and Calcium in conditions where chronic hypoparathyroidism affects mineral regulation. Studies, including randomized controlled trials (RCTs) and observational reports, evaluated adults by monitoring changes in serum calcium and phosphate concentrations and excretion patterns. Findings describe observed patterns in mineral concentration levels over the study duration. However, sample sizes were modest in many controlled studies, meaning results apply only to the specific populations studied, and there is limited information for long-term outcomes reflecting changes in daily functioning.


Evidence for Bone Disorder in Chronic Kidney Disease

Research also examined Dihydrotachysterol and Calcium in the context of metabolic bone disorder and mineral changes related to chronic kidney disease. Evidence includes systematic reviews and historical documentation, monitoring outcomes like Parathyroid Hormone (PTH) levels and changes in bone pathology as assessed by bone biopsy. Data show patterns related to PTH concentrations in the studied populations. Comparative evidence is lacking against newer therapeutic options, and follow-up durations were limited in many key studies, meaning there is limited information on specific fracture prevention.


Long-Term Studies and Research Uncertainty

Follow-up durations were limited in many controlled settings. Long-term observational evidence describes patterns in mineral concentrations over years, but these findings describe group patterns, not personal outcomes. Certainty remains low regarding the sustained long-term effects on clinical endpoints. The combination was evaluated in some special populations, including children with bone disorder related to chronic kidney disease. However, data for certain groups remain insufficient and sample sizes were modest. Overall, research highlights what is known—and what is still uncertain—about this management strategy.

Key Studies & References

  1. WHO Anatomical Therapeutic Chemical (ATC) Classification for Dihydrotachysterol (A11CC02)

Frequently Asked Questions (FAQ)

Common questions about Osteofos (FAQ)

Q: How quickly does Osteofos start working for bone density?

A: Studies and official information indicate that the active components begin to affect the body's mineral levels shortly after treatment starts. Specifically for the Vitamin D analog component, a peak effect on mineral balance is typically observed after approximately mathbf1 month of daily use. This is the approximate timeframe when effects on mineral regulation, which are necessary for bone health, are typically observed.


Q: Is it normal to have mild stomach upset after taking Osteofos?

A: Gastrointestinal reactions are formally reported in regulatory documents, although they are generally classified as mathbfRare (occurring in 0.1% or less of patients). These reported effects include mathbfnausea, mathbfconstipation, and mathbfabdominal pain. If symptoms such as persistent stomach upset occur, it is important that this is discussed with a healthcare professional.


Q: Can Osteofos be taken with vitamins?

A: The official product information states that concurrent use with mathbfOther Vitamin D Analogs is generally mathbfto be avoided. This is because the medicine already contains a Vitamin D analog (Dihydrotachysterol) and combining them could potentially lead to mathbfhypercalcaemia (elevated calcium levels). Specific interactions with other general vitamins are not explicitly stated in core regulatory documents.


Q: Why do doctors recommend standing up after taking the pill?

A: Regulatory instructions for similar combination products often advise remaining in an mathbfupright position (sitting or standing) for at least mathbf30 minutes after administration. This requirement is in place to help ensure the tablet passes fully into the stomach and to minimize the potential for irritation to the lining of the esophagus.


Q: Does Osteofos affect dental health?

A: The active ingredients are Calcium Carbonate and Dihydrotachysterol. However, for similar combination products used for bone health that contain bisphosphonates, there have been mathbfrare reports of osteonecrosis of the jaw (ONJ), which is a serious jaw bone condition. Any dental concerns should be discussed with a healthcare professional.


Q: How long do most people stay on Osteofos treatment?

A: The drug is prescribed for a mathbflong-term maintenance phase to manage chronic mineral imbalances. While the clinical data supporting the efficacy of similar treatments has been evaluated over several years, the optimal duration of use for Osteofos is mathbfnot fully determined. The continuation of treatment is determined by a healthcare provider based on the patient's individual needs and response.


Q: Will Osteofos prevent all future bone fractures?

A: Studies on the components of Osteofos or similar products show that treatment can lead to an mathbfincrease in bone mass and a mathbfreduction in the incidence of certain fractures. However, official information notes that while risk is reduced, the medicine does mathbfnot prevent all types of future bone fractures.


Q: Is it okay to lie down right after taking Osteofos?

A: Official administration instructions for this type of medication strongly recommend mathbfnot lying down for at least mathbf30 minutes after taking the tablet. This instruction is provided to help ensure safe passage of the tablet to the stomach and to avoid irritation of the esophagus.


Q: Can taking Osteofos cause joint pain?

A: The official adverse reaction lists mathbfmuscle or bone pain as a possible symptom associated with mathbfhypercalcaemia (high calcium levels), which is a potential side effect. mathbfJoint pain specifically is mathbfnot listed as a common adverse reaction for the active ingredients.


Q: What are the serious but rare side effects of Osteofos?

A: The most serious risks are associated with mathbfchronic or severe hypercalcaemia (elevated blood calcium levels). These serious adverse reactions include mathbfirreversible kidney damage and generalized mathbfsoft tissue calcification (calcium deposits in soft tissues), as noted in regulatory safety information.


Q: Do you need Vitamin D along with Osteofos?

A: No, Osteofos already contains the active component mathbfDihydrotachysterol, which is a mathbfVitamin D analog designed to help regulate calcium. Official documents advise mathbfavoiding concurrent use of mathbfother Vitamin D Analogs due to the potential for mathbfhypercalcaemia (elevated calcium levels in the blood).


Q: Is Osteofos known to cause heartburn?

A: Regulatory documents list mathbfGastrointestinal Disorders such as nausea and abdominal pain as possible adverse effects. However, the specific term mathbfheartburn (gastroesophageal reflux) is mathbfnot explicitly listed as a common or reported adverse reaction for the active ingredients.


Q: Can people with a history of ulcers take Osteofos?

A: Official information for similar combination products containing bisphosphonates recommends caution for individuals with mathbfactive upper gastrointestinal conditions, such as ulcers or severe irritation. Eligibility for use is determined by a healthcare professional.


Q: Can Osteofos be taken with coffee or juice?

A: For similar combination products, it is often necessary to take the tablet only with mathbfplain water and mathbfat least 30 minutes before any food or drink (other than water). Additionally, mathbfGrapefruit juice specifically may mathbfalter the blood levels and effects of the Dihydrotachysterol component.


Q: Are headaches a common side effect of Osteofos?

A: Official information reports mathbfheadache as a possible early symptom of mathbfhypercalcaemia (high blood calcium levels), which is the primary adverse risk of the medication. The frequency of headaches generally is mathbfnot explicitly classified in the standard adverse reaction tables for the active ingredients.


Q: Does Osteofos cause fatigue?

A: Yes, mathbffatigue or weakness is reported in official documents as a possible symptom that may occur with mathbfhypercalcaemia (high blood calcium levels). This indicates that it may be related to the mineral imbalance that the drug manages.


Q: How is Osteofos eliminated from the body?

A: According to the official pharmacokinetics data, the metabolites (breakdown products) of Vitamin D analogs like Dihydrotachysterol are primarily eliminated from the body through the mathbfbile and feces.


Q: Are there any specific blood tests required while on Osteofos?

A: Yes, regulatory guidelines mandate mathbffrequent monitoring through blood tests. This includes checking mathbfserum calcium levels one to two times per week during the initial dose adjustment phase and at least monthly once the maintenance dose is stable.


Q: Does Osteofos affect hormone levels?

A: The drug is intended to support the body's natural mineral balance system, which is closely regulated by mathbfParathyroid Hormone (PTH). Therefore, the medicine's action mathbfaffects the levels and function of PTH, and monitoring PTH is a recognized outcome assessment in relevant studies.


Q: Are there any known interactions with thyroid medication and Osteofos?

A: Official interaction documents note that the mathbfCalcium Carbonate component can interact with mathbfthyroid hormones (like levothyroxine). Concurrent administration may mathbfdecrease the effectiveness of the thyroid medicine, and a specific mathbftiming separation between the doses is often required as part of the management strategy.


Q: Is confusion a possible side effect of Osteofos?

A: Official information indicates that mathbfmental confusion is reported as a symptom, often occurring with more severe or persistent mathbfhypercalcaemia (elevated calcium levels in the blood) or drug toxicity.


Q: What time of day is best to take Osteofos?

A: Official dosing instructions require that the medicine be taken mathbfonce daily. For similar combination products, it is often required to be taken mathbfat least 30 minutes before the first food or drink of the day, which generally directs administration to the morning.


Q: Is it safe to take over-the-counter pain relievers with Osteofos?

A: Official guidance notes that mathbfcaution and mathbfmonitoring may be required when similar combination products are taken with certain mathbfNonsteroidal Anti-Inflammatory Drugs (NSAIDs) and mathbfAspirin. Any use of over-the-counter medications, including pain relievers, should be reviewed by a healthcare professional.


Q: Will stopping Osteofos suddenly have any effect?

A: Official safety information notes that the mathbftoxic effects from the Vitamin D component (Dihydrotachysterol) may mathbfpersist for up to one month after discontinuation. This indicates that the effects related to the Vitamin D analog component may not disappear immediately upon stopping the medicine.


Q: Are there any known interactions between Osteofos and antacids?

A: Yes, official drug interaction warnings advise mathbfavoiding antacids that contain magnesium or calcium. Taking these with Osteofos can interfere with the metabolism of Dihydrotachysterol or potentially increase calcium levels, which could lead to mathbfhypercalcaemia.

How should Osteofos be stored and disposed of?

Storage and Disposal of Osteofos

The storage of Osteofos (Calcium Carbonate and Dihydrotachysterol) must strictly comply with official regulatory guidelines to maintain the product's integrity and labeled shelf life.

Required Storage Conditions

The medicine must be stored at a temperature not exceeding 30 C. To protect the active ingredients, the product must be protected from light and stored in a dry place. It is required to keep Osteofos in the original package to ensure this protection. The official shelf life is 3 years when stored under these conditions.

Safety and Disposal

To prevent accidental exposure, Osteofos must be kept out of the sight and reach of children (store locked up). For disposal of unused or expired medicine, the label indicates no special requirements are necessary, and the product should be disposed of according to standard local guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Osteofos found in:

A-Z Index: